vTv Therapeutics Inc. - (VTVT): Price and Financial Metrics
VTVT Price/Volume Stats
| Current price | $14.26 | 52-week high | $30.99 |
| Prev. close | $14.69 | 52-week low | $7.38 |
| Day low | $14.26 | Volume | 6,100 |
| Day high | $14.99 | Avg. volume | 38,945 |
| 50-day MA | $17.05 | Dividend yield | N/A |
| 200-day MA | $17.04 | Market Cap | 42.92M |
VTVT Stock Price Chart Interactive Chart >
vTv Therapeutics Inc. - (VTVT) Company Bio
vTv Therapeutics Inc., a biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company was founded in 2015 and is based in High Point, North Carolina.
Latest VTVT News From Around the Web
Below are the latest news stories about VTV THERAPEUTICS INC that investors may wish to consider to help them evaluate VTVT as an investment opportunity.
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate UpdateHIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments. “Our newly appointed Chief Medical Officer, Dr. Thomas Strack, who has been working with us on |
vTv Therapeutics to Participate at the Stifel 2023 Healthcare ConferenceHIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that its Chief Financial Officer, Steven Tuch, its Chief Scientific Officer, Carmen Valcarce, and its Chief Medical Officer, Thomas Strack, will be presenting at the Stifel 2023 Healthcare Conference on November 15, |
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical OfficerHIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, effective immediately. “I am pleased to welcome Dr. Strack to the vTv team,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutic |
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 MillionHIGH POINT, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that it has entered into a common stock repurchase agreement with Reneo Pharmaceuticals, Inc. through which Reneo has purchased all of its common stock that was granted to vTv under the Reneo License Agreement for to |
One vTv Therapeutics Insider Raised Their Stake In The Previous YearFrom what we can see, insiders were net buyers in vTv Therapeutics Inc.'s ( NASDAQ:VTVT ) during the past 12 months... |
VTVT Price Returns
| 1-mo | 5.71% |
| 3-mo | -32.16% |
| 6-mo | -29.13% |
| 1-year | -19.91% |
| 3-year | -79.39% |
| 5-year | -79.86% |
| YTD | 24.00% |
| 2023 | -56.62% |
| 2022 | -33.39% |
| 2021 | -46.51% |
| 2020 | 9.41% |
| 2019 | -35.85% |
Continue Researching VTVT
Want to see what other sources are saying about vTv Therapeutics Inc's financials and stock price? Try the links below:vTv Therapeutics Inc (VTVT) Stock Price | Nasdaq
vTv Therapeutics Inc (VTVT) Stock Quote, History and News - Yahoo Finance
vTv Therapeutics Inc (VTVT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...